Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats

• Published in: Disease models & mechanisms Vol. 5; no. 5; pp. 660 - 670
• Main Authors: Decara, Juan Manuel, Romero-Cuevas, Miguel, Rivera, Patricia, Macias-González, Manuel, Vida, Margarita, Pavón, Francisco J, Serrano, Antonia, Cano, Carolina, Fresno, Nieves, Pérez-Fernández, Ruth, Rodríguez de Fonseca, Fernando, Suárez, Juan
• Format: Journal Article
• Language: English
• Published: England The Company of Biologists Ltd 01.09.2012; The Company of Biologists Limited; The Company of Biologists
• Subjects: Adipocytes; Adipose Tissue, Brown - drug effects; Adipose Tissue, Brown - metabolism; Adipose Tissue, White - drug effects; Adipose Tissue, White - metabolism; Amides - administration & dosage; Amides - chemistry; Amides - pharmacology; Animals; Blood Glucose - metabolism; Body weight gain; Cholesterol - blood; Crystal structure; Drug dosages; Feeding Behavior - drug effects; Food; Gene Expression Profiling; Gene Expression Regulation - drug effects; Glucose Tolerance Test; Humans; Hydrogen Bonding - drug effects; Hydrogen bonds; Insulin; Insulin - blood; Insulin Resistance; Ligands; Lipids; Liver - drug effects; Liver - metabolism; Male; Models, Molecular; Obesity; Oleic Acids - administration & dosage; Oleic Acids - chemistry; Oleic Acids - pharmacology; Oxazoles - chemistry; Oxazoles - pharmacology; Pharmaceuticals; PPAR alpha - agonists; PPAR alpha - metabolism; Protein Binding - drug effects; Rats; Solutions; Sulfonamides - administration & dosage; Sulfonamides - chemistry; Sulfonamides - pharmacology; Taste; Thermogenesis - drug effects; Thermogenesis - genetics; Tyrosine - analogs & derivatives; Tyrosine - chemistry; Tyrosine - pharmacology; Weight Gain - drug effects

We have modelled elaidyl-sulfamide (ES), a sulfamoyl analogue of oleoylethanolamide (OEA). ES is a lipid mediator of satiety that works through the peroxisome proliferator-activated receptor alpha (PPARα). We have characterised the pharmacological profile of ES (0.3-3 mg/kg body weight) by means of...